NDA 220641 · Corcept Therap
Lifyorli (Copackaged)
Relacorilant · Oral
NovelLast checked: Nov 19, 2026Latest source record: Mar 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Mar 25, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
26
4 Phase 3, 3 recruiting
FAERS reports
99
71 serious, 22 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2026.
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )] . LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. ( 1 , 14 )
Mechanism: Relacorilant is a reversible glucocorticoid receptor (GR) antagonist. In functional in vitro assays with the mineralocorticoid receptor, relacorilant showed no agonist or antagonist activity. In human cell-line derived xenograft models, relacorilant enhanced apoptosis and antitumor activity when administered with paclitaxel. Cortisol binding to the GR is immunosuppressive, decreasing secretion of pro‑inflammatory cytokines. GR antagonism may indirectly activate the immune system; relacorilant inhibited the cortisol-induced reduction of tumor necrosis factor alpha and interferon gamma in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LIFYORLI (COPACKAGED) · RELACORILANT 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Relacorilant" as an intervention, any sponsor and status, largest first.
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerPivotal-lookingActive, not recruiting
Corcept TherapeuticsIndustry
NCT05257408 · 381 participants · Start Jun 29, 2022 · Primary completion Mar 31, 2025
Drug: Relacorilant 150 mg; Nab-paclitaxel 80 mg/m^2 and 1 more · For: Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Sites: Phoenix, Arizona; Tucson, Arizona; Irvine, California · 116 sites in all
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruiting
Corcept TherapeuticsIndustry
NCT06906341 · 270 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 2027
Drug: Relacorilant 150 mg once daily (QD); Nab-paclitaxel 80 mg/m^2 and 1 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms and 1 more
Sites: Birmingham, Alabama; Palo Alto, California; San Francisco, California · 53 sites in all
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerPivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT03776812 · 178 participants · Start Apr 5, 2019 · Primary completion Mar 16, 2021
Drug: Relacorilant; Nab-paclitaxel · For: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Carcinoma; Recurrent Primary Peritoneal Carcinoma
Sites: Birmingham, Alabama; Scottsdale, Arizona; Denver, Colorado · 24 sites in all
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromePivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT03697109 · 152 participants · Start Nov 15, 2018 · Primary completion Apr 8, 2024
Drug: Relacorilant · For: Cushing Syndrome
Sites: Phoenix, Arizona; Los Angeles, California; Torrance, California · 64 sites in all
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasPivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT04308590 · 137 participants · Start Jul 27, 2020 · Primary completion Sep 19, 2024
Drug: Relacorilant · For: Hypercortisolism
Sites: Birmingham, Alabama; Stanford, California; Torrance, California · 45 sites in all
- CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)Pivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT03508635 · 130 participants · Start Sep 2014 · Primary completion Dec 2015
Drug: CORT125134; Matching Placebo of CORT125134 and 3 more · For: Healthy
Sites: Nottingham, United Kingdom
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruiting
Corcept TherapeuticsIndustry
NCT03604198 · 125 participants · Start May 7, 2018 · Primary completion Dec 2026
Drug: relacorilant · For: Cushing Syndrome
Sites: Phoenix, Arizona; Stanford, California; Torrance, California · 48 sites in all
University of ChicagoAcademic, hospital or other
NCT05726292 · 90 participants (planned) · Start Jan 6, 2025 · Primary completion Oct 1, 2027
Drug: Relacorilant; Enzalutamide · For: Prostate Cancer; Prostate Adenocarcinoma
Sites: Chicago, Illinois; Evanston, Illinois; Portland, Oregon · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia13
- death12
- nausea12
- stomatitis11
- vomiting10
- diarrhoea9
- fatigue7
- pneumonia6
- ascites5
- mucosal inflammation5
- dehydration4
- off label use4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 96 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N, Van Gorp T, Matulonis UA, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Borazanci EH, Bahary N, Chung V, et al. · Oncologist 2024 · Clinical Trial, Phase III, Multicenter Study
- Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Munster PN, Greenstein AE, Fleming GF, et al. · Clin Cancer Res 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
Lesnock JL, Temin S, Bouberhan S, et al. · J Clin Oncol 2026 · Practice Guideline, Systematic Review
- Relacorilant or surgery improved hemostatic markers in Cushing syndrome.
Simeoli C, Di Paola N, Stigliano A, et al. · J Endocrinol Invest 2025 · Clinical Trial, Phase II
Sponsor: Corcept Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.